[go: up one dir, main page]

AR088297A1 - R(+)-n-formil-propargil-aminoindano - Google Patents

R(+)-n-formil-propargil-aminoindano

Info

Publication number
AR088297A1
AR088297A1 ARP120103781A ARP120103781A AR088297A1 AR 088297 A1 AR088297 A1 AR 088297A1 AR P120103781 A ARP120103781 A AR P120103781A AR P120103781 A ARP120103781 A AR P120103781A AR 088297 A1 AR088297 A1 AR 088297A1
Authority
AR
Argentina
Prior art keywords
propargil
aminoindano
formil
aminoindane
propargyl
Prior art date
Application number
ARP120103781A
Other languages
English (en)
Inventor
Keisar Michal
Licht Danit
Lidor-Hadas Ramy
Zholkovsky Marina
Frenkel Anton
Bahar Eliezer
Safadi Muhammad
Cohen Rachel
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR088297A1 publication Critical patent/AR088297A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee R(+)-N-formil-propargil-aminoindano o una sal farmacéuticamente aceptable del mismo y una composición que contiene N-propargil-1(R)-aminoindano o una sal farmacéuticamente aceptable del mismo, y un compuesto de R(+)-N-formil-propargil-aminoindano.
ARP120103781A 2011-10-10 2012-10-10 R(+)-n-formil-propargil-aminoindano AR088297A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10

Publications (1)

Publication Number Publication Date
AR088297A1 true AR088297A1 (es) 2014-05-21

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103781A AR088297A1 (es) 2011-10-10 2012-10-10 R(+)-n-formil-propargil-aminoindano

Country Status (15)

Country Link
US (1) US9346746B2 (es)
EP (1) EP2766002A4 (es)
JP (1) JP2014534196A (es)
KR (1) KR20140090996A (es)
CN (1) CN103874487A (es)
AR (1) AR088297A1 (es)
AU (1) AU2012323349A1 (es)
BR (1) BR112014008555A2 (es)
CA (1) CA2851276A1 (es)
EA (1) EA201490761A1 (es)
HK (1) HK1200315A1 (es)
IL (1) IL231721A0 (es)
MX (1) MX2014004308A (es)
WO (1) WO2013055687A2 (es)
ZA (1) ZA201403043B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
SG187455A1 (en) * 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
WO2011042812A1 (en) * 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
US20110152381A1 (en) * 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) * 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
WO1998027055A1 (en) 1996-12-18 1998-06-25 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
EP1242066B1 (en) * 1999-10-27 2006-06-28 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
WO2004072250A2 (en) 2003-02-06 2004-08-26 University Of Georgia Research Foundation, Inc. Galacturonosyl transferases, nucleic acids encoding same and uses therefor
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
KR20170023211A (ko) 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
CN101622225B (zh) 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
KR101077835B1 (ko) 2006-12-14 2011-10-28 테바 파마슈티컬 인더스트리즈 리미티드 라사길린의 타닌산염
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
SG187455A1 (en) 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
JP2011524353A (ja) 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
BRPI0909894A2 (pt) 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
AU2009260733B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
WO2011042812A1 (en) 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
US20110152381A1 (en) 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
WO2012015950A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
CN103188933A (zh) 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
KR20140074388A (ko) 2011-10-10 2014-06-17 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 시트라마이드
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Also Published As

Publication number Publication date
ZA201403043B (en) 2015-08-26
KR20140090996A (ko) 2014-07-18
EP2766002A4 (en) 2015-07-01
BR112014008555A2 (pt) 2017-04-18
US20130089612A1 (en) 2013-04-11
WO2013055687A3 (en) 2013-07-25
CN103874487A (zh) 2014-06-18
IL231721A0 (en) 2014-05-28
MX2014004308A (es) 2014-07-24
JP2014534196A (ja) 2014-12-18
WO2013055687A2 (en) 2013-04-18
CA2851276A1 (en) 2013-04-18
AU2012323349A1 (en) 2014-05-22
EP2766002A2 (en) 2014-08-20
US9346746B2 (en) 2016-05-24
EA201490761A1 (ru) 2014-11-28
NZ624206A (en) 2016-11-25
HK1200315A1 (en) 2015-08-07

Similar Documents

Publication Publication Date Title
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
JOP20180102B1 (ar) مركب صيدلاني
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
MX2016006336A (es) Compuestos pirazolopirimidina.
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20150887A1 (es) Compuestos de benceno sustituidos
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CR20130539A (es) Triazolopiridinas
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
AU2014207408A8 (en) Pharmaceutical compositions comprising nitroxyl donors
DOP2014000250A (es) Nuevos compuestos de pirazol
CR20140380A (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
GT201300241A (es) Composicion farmaceutica antihipertensiva
AR095097A1 (es) Compuestos de fenoxietoxi
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas

Legal Events

Date Code Title Description
FB Suspension of granting procedure